MedGenome Inc.
Antibody Discovery Services
FromMedGenome Inc.
Antibody discovery is an important component for early-stage research studies, diagnostics, and therapeutics. Hybridoma technology has been the forefront tool in generating monoclonal antibodies but is time consuming and costly. MedGenome’s proprietary HitMab platform now enables researchers to identify antigen-specific antibodies in less than 6 months’ time.
Most popular related searches
antigen specificity
antigen specific
monoclonal antibody
recombinant antibody
validated antibody
antigen antibody
bioinformatics
Streamlined High-Throughput Monoclonal AntiBody discovery service
- Recombinant antibodies generated from antigen-specific B cells
- Paired information of heavy and light chain antibodies for greater specificity
- Generate antibodies for low or poorly immunogenic proteins
- Reduced timelines for lead discovery using high throughput single-cell BCR sequencing
Advance your research with our accelerated timelines
Reduce your wait time from 8-10 months with traditional Hybridoma technology to 4-6 month using HitMab service.
Ordering and Antibodies Delivery
- Deliverables include a complete report outlining antibody sequencing and bioinformatics process with ELISA validation data.
- Up to 5 purified, ELISA-validated antibodies will be delivered for each antigen of interest. Additional antibodies can be synthesized on request.